An NIAID-sponsored study of a Lilly antibody has been paused for possible toxicity, prompting speculation over the cause of the problem.
Lilly’s doublet might be superior to Regeneron’s cocktail, but timing and manufacturing issues could now come into play.
October brings US approval decisions for Eysuvis and Brilinta, while a panel meeting sets up a discussion around Covid-19 vaccines.
Like Lilly Regeneron reports promising but not emphatic data with its antibody treatment, and the question turns to approvability.
LY-CoV555 shows promising signs for the antibody approach, with Regeneron not far behind.
The upcoming virtual Esmo congress gives top billing to big pharma immunotherapies.